CovidChloroV1, Main, Corpus, bibRecord, 000981

The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.

Identifieur interne : 000981 ( Main/Corpus ); précédent : 000980; suivant : 000982

The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.

Auteurs : Gerardo Casucci ; Domenico Acanfora ; Raffaele Antonelli Incalzi

Source :

Drugs & aging [ 1179-1969 ] ; 2020.

RBID : pubmed:33084001

English descriptors

KwdEn :
- Aged (MeSH), Angiotensin Receptor Antagonists (pharmacology), Angiotensin-Converting Enzyme 2 (MeSH), Angiotensin-Converting Enzyme Inhibitors (pharmacology), Betacoronavirus (drug effects), Betacoronavirus (physiology), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (immunology), Coronavirus Infections (metabolism), Coronavirus Infections (virology), Cytokine Release Syndrome (drug therapy), Cytokine Release Syndrome (immunology), Humans (MeSH), Hypertension (drug therapy), Immunologic Factors (pharmacology), Inflammation (drug therapy), Inflammation (immunology), Neprilysin (antagonists & inhibitors), Pandemics (MeSH), Peptidyl-Dipeptidase A (metabolism), Pneumonia, Viral (drug therapy), Pneumonia, Viral (immunology), Pneumonia, Viral (metabolism), Pneumonia, Viral (virology), Renin-Angiotensin System (drug effects), SARS-CoV-2 (MeSH).
MESH :
- chemical , antagonists & inhibitors : Neprilysin.
- chemical , metabolism : Peptidyl-Dipeptidase A.
- chemical , pharmacology : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Immunologic Factors.
- drug effects : Betacoronavirus, Renin-Angiotensin System.
- drug therapy : Coronavirus Infections, Cytokine Release Syndrome, Hypertension, Inflammation, Pneumonia, Viral.
- immunology : Coronavirus Infections, Cytokine Release Syndrome, Inflammation, Pneumonia, Viral.
- metabolism : Coronavirus Infections, Pneumonia, Viral.
- physiology : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Aged, Angiotensin-Converting Enzyme 2, COVID-19, Humans, Pandemics, SARS-CoV-2.

Abstract

This paper presents a brief overview of the complex interaction between age, hypertension, the renin-angiotensin-aldosterone system (RAAS), inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Coronavirus disease 2019 (COVID-19) is more frequent and more severe in comorbid elderly patients, especially those with hypertension, diabetes, obesity, or cardiovascular diseases. There are concerns regarding the use of RAAS inhibitors in patients with COVID-19. Some physicians have considered the need for interrupting RAAS inhibition in order to reduce the possibility of SARS-CoV2 entering lung cells after binding to angiotensin-converting enzyme 2 (ACE2) receptors. We offer a different point of view in relation to the need for continuing to use RAAS inhibitors in patients with COVID-19. We focused our article on elderly patients because of the distinctive imbalance between the immune response, which is depressed, and the exacerbated inflammatory response, 'inflammaging', which makes the geriatric patient an appropriate candidate for therapeutic strategies aimed at modulating the inflammatory response. Indeed, COVID-19 is an inflammatory storm that starts and worsens during the course of the disease. During the COVID-19 pandemic, various therapeutic approaches have been tested, including antiviral drugs, interferon, anti-interleukins, hydroxychloroquine, anti-inflammatories, immunoglobulins from recovered patients, and heparins. Some of these therapeutic approaches did not prove to be beneficial, or even induced serious complications. Based on current evidence, in the early stages of the disease modulation of the inflammatory response through the inhibition of neprilysin and modulation of the RAAS could affect the course and outcome of COVID-19.

DOI: 10.1007/s40266-020-00808-4
PubMed: 33084001
PubMed Central: PMC7575413

Links to Exploration step

pubmed:33084001

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.</title>
<author><name sortKey="Casucci, Gerardo" sort="Casucci, Gerardo" uniqKey="Casucci G" first="Gerardo" last="Casucci">Gerardo Casucci</name>
<affiliation><nlm:affiliation>Unit of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037, Telese Terme, BN, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Acanfora, Domenico" sort="Acanfora, Domenico" uniqKey="Acanfora D" first="Domenico" last="Acanfora">Domenico Acanfora</name>
<affiliation><nlm:affiliation>Unit of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037, Telese Terme, BN, Italy. domenico.acanfora29@gmail.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Incalzi, Raffaele Antonelli" sort="Incalzi, Raffaele Antonelli" uniqKey="Incalzi R" first="Raffaele Antonelli" last="Incalzi">Raffaele Antonelli Incalzi</name>
<affiliation><nlm:affiliation>Unit of Geriatrics, Policlinico Universitario Campus Bio-Medico di Roma, Via Álvaro del Portillo 21, 00128, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33084001</idno>
<idno type="pmid">33084001</idno>
<idno type="doi">10.1007/s40266-020-00808-4</idno>
<idno type="pmc">PMC7575413</idno>
<idno type="wicri:Area/Main/Corpus">000981</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000981</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.</title>
<author><name sortKey="Casucci, Gerardo" sort="Casucci, Gerardo" uniqKey="Casucci G" first="Gerardo" last="Casucci">Gerardo Casucci</name>
<affiliation><nlm:affiliation>Unit of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037, Telese Terme, BN, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Acanfora, Domenico" sort="Acanfora, Domenico" uniqKey="Acanfora D" first="Domenico" last="Acanfora">Domenico Acanfora</name>
<affiliation><nlm:affiliation>Unit of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037, Telese Terme, BN, Italy. domenico.acanfora29@gmail.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Incalzi, Raffaele Antonelli" sort="Incalzi, Raffaele Antonelli" uniqKey="Incalzi R" first="Raffaele Antonelli" last="Incalzi">Raffaele Antonelli Incalzi</name>
<affiliation><nlm:affiliation>Unit of Geriatrics, Policlinico Universitario Campus Bio-Medico di Roma, Via Álvaro del Portillo 21, 00128, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Drugs & aging</title>
<idno type="eISSN">1179-1969</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term>
<term>Angiotensin Receptor Antagonists (pharmacology)</term>
<term>Angiotensin-Converting Enzyme 2 (MeSH)</term>
<term>Angiotensin-Converting Enzyme Inhibitors (pharmacology)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (physiology)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (metabolism)</term>
<term>Coronavirus Infections (virology)</term>
<term>Cytokine Release Syndrome (drug therapy)</term>
<term>Cytokine Release Syndrome (immunology)</term>
<term>Humans (MeSH)</term>
<term>Hypertension (drug therapy)</term>
<term>Immunologic Factors (pharmacology)</term>
<term>Inflammation (drug therapy)</term>
<term>Inflammation (immunology)</term>
<term>Neprilysin (antagonists & inhibitors)</term>
<term>Pandemics (MeSH)</term>
<term>Peptidyl-Dipeptidase A (metabolism)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Pneumonia, Viral (metabolism)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Renin-Angiotensin System (drug effects)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neprilysin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Peptidyl-Dipeptidase A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Angiotensin Receptor Antagonists</term>
<term>Angiotensin-Converting Enzyme Inhibitors</term>
<term>Immunologic Factors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
<term>Renin-Angiotensin System</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Hypertension</term>
<term>Inflammation</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Inflammation</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Angiotensin-Converting Enzyme 2</term>
<term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This paper presents a brief overview of the complex interaction between age, hypertension, the renin-angiotensin-aldosterone system (RAAS), inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Coronavirus disease 2019 (COVID-19) is more frequent and more severe in comorbid elderly patients, especially those with hypertension, diabetes, obesity, or cardiovascular diseases. There are concerns regarding the use of RAAS inhibitors in patients with COVID-19. Some physicians have considered the need for interrupting RAAS inhibition in order to reduce the possibility of SARS-CoV2 entering lung cells after binding to angiotensin-converting enzyme 2 (ACE2) receptors. We offer a different point of view in relation to the need for continuing to use RAAS inhibitors in patients with COVID-19. We focused our article on elderly patients because of the distinctive imbalance between the immune response, which is depressed, and the exacerbated inflammatory response, 'inflammaging', which makes the geriatric patient an appropriate candidate for therapeutic strategies aimed at modulating the inflammatory response. Indeed, COVID-19 is an inflammatory storm that starts and worsens during the course of the disease. During the COVID-19 pandemic, various therapeutic approaches have been tested, including antiviral drugs, interferon, anti-interleukins, hydroxychloroquine, anti-inflammatories, immunoglobulins from recovered patients, and heparins. Some of these therapeutic approaches did not prove to be beneficial, or even induced serious complications. Based on current evidence, in the early stages of the disease modulation of the inflammatory response through the inhibition of neprilysin and modulation of the RAAS could affect the course and outcome of COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">33084001</PMID>
<DateCompleted><Year>2020</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1969</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>37</Volume>
<Issue>11</Issue>
<PubDate><Year>2020</Year>
<Month>11</Month>
</PubDate>
</JournalIssue>
<Title>Drugs & aging</Title>
<ISOAbbreviation>Drugs Aging</ISOAbbreviation>
</Journal>
<ArticleTitle>The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.</ArticleTitle>
<Pagination><MedlinePgn>779-785</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s40266-020-00808-4</ELocationID>
<Abstract><AbstractText>This paper presents a brief overview of the complex interaction between age, hypertension, the renin-angiotensin-aldosterone system (RAAS), inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Coronavirus disease 2019 (COVID-19) is more frequent and more severe in comorbid elderly patients, especially those with hypertension, diabetes, obesity, or cardiovascular diseases. There are concerns regarding the use of RAAS inhibitors in patients with COVID-19. Some physicians have considered the need for interrupting RAAS inhibition in order to reduce the possibility of SARS-CoV2 entering lung cells after binding to angiotensin-converting enzyme 2 (ACE2) receptors. We offer a different point of view in relation to the need for continuing to use RAAS inhibitors in patients with COVID-19. We focused our article on elderly patients because of the distinctive imbalance between the immune response, which is depressed, and the exacerbated inflammatory response, 'inflammaging', which makes the geriatric patient an appropriate candidate for therapeutic strategies aimed at modulating the inflammatory response. Indeed, COVID-19 is an inflammatory storm that starts and worsens during the course of the disease. During the COVID-19 pandemic, various therapeutic approaches have been tested, including antiviral drugs, interferon, anti-interleukins, hydroxychloroquine, anti-inflammatories, immunoglobulins from recovered patients, and heparins. Some of these therapeutic approaches did not prove to be beneficial, or even induced serious complications. Based on current evidence, in the early stages of the disease modulation of the inflammatory response through the inhibition of neprilysin and modulation of the RAAS could affect the course and outcome of COVID-19.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Casucci</LastName>
<ForeName>Gerardo</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Unit of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037, Telese Terme, BN, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Acanfora</LastName>
<ForeName>Domenico</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Unit of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037, Telese Terme, BN, Italy. domenico.acanfora29@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Incalzi</LastName>
<ForeName>Raffaele Antonelli</ForeName>
<Initials>RA</Initials>
<AffiliationInfo><Affiliation>Unit of Geriatrics, Policlinico Universitario Campus Bio-Medico di Roma, Via Álvaro del Portillo 21, 00128, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>New Zealand</Country>
<MedlineTA>Drugs Aging</MedlineTA>
<NlmUniqueID>9102074</NlmUniqueID>
<ISSNLinking>1170-229X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber>
<NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012084" MajorTopicYN="N">Renin-Angiotensin System</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>09</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>10</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>7</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33084001</ArticleId>
<ArticleId IdType="doi">10.1007/s40266-020-00808-4</ArticleId>
<ArticleId IdType="pii">10.1007/s40266-020-00808-4</ArticleId>
<ArticleId IdType="pmc">PMC7575413</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Eur Heart J. 2005 Feb;26(4):369-75; discussion 322-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15671045</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 30;395(10238):1705-1714</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32416785</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Coll Cardiol. 2020 Jul 21;76(3):268-276</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32470515</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Heart J. 2020 May 14;41(19):1810-1817</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32388565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol Sin. 2020 Jun;35(3):256-258</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32034638</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mayo Clin Proc. 2020 Jun;95(6):1222-1230</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32376099</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mayo Clin Proc. 2020 Sep;95(9):2040-2042</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32861346</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gut. 2005 Dec;54(12):1790-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16166274</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2431-2440</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32356627</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2020 Feb 17;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32081428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2441-2448</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32356628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Drug Investig. 2020 May;40(5):493-501</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32193801</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2003 Apr;41(4):871-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12654716</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Res. 2020 Aug 1;116(10):1688-1699</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32293003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res. 2017 Nov;125(Pt A):21-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28619367</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2019 Jul;25(7):1153-1163</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31209336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Jul 1;5(7):811-818</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219356</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2020 Jun 4;55(6):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32269086</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Pharmacol. 2006 Jun;6(3):271-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16581295</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):757-760</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32228222</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Pharm Des. 2003;9(9):715-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12570789</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2002 Jun 20;417(6891):822-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12075344</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2003 Mar;41(3):392-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12623933</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Elife. 2020 Feb 03;9:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32011232</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):e102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32356626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Microbiol. 2019 Dec 03;10:2752</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31849894</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2020 May 1;130(5):2202-2205</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Res. 2000 Sep 1;87(5):E1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10969042</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Aug;87(16):9379-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23785207</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Jul 7;436(7047):112-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16001071</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Jul 1;5(7):825-830</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32324209</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Sep 1;5(9):1020-1026</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32936273</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2005 Aug;11(8):875-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16007097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2020 Jul 1;180(7):934-943</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbes Infect. 2020 Mar;22(2):80-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32087334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2000 Oct 27;275(43):33238-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10924499</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):e21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Endocrinol. 2018 Oct;14(10):576-590</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30046148</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Medicine (Baltimore). 2018 Jun;97(25):e11152</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29924020</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Appl Pharmacol. 2010 May 15;245(1):100-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20178811</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2019 Apr 24;9(1):6509</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31019233</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 May;8(5):475-481</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32105632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):135-136</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32282032</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Res. 2020 Jun 5;126(12):1671-1681</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32302265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2020 May 7;55(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32269088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2020 Jul;251(3):228-248</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32418199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 23;382(17):1653-1659</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227760</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 May;20(5):515-516</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32213336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JCI Insight. 2016 Dec 8;1(20):e90558</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27942595</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Mar;579(7798):265-269</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015508</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000981 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000981 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:33084001
   |texte=   The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:33084001" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.

The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki